Project Grant R34HL138110

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $869,696 to Vanderbilt University Medical Center to investigate the relationship between preeclampsia during pregnancy and the development of heart failure with preserved ejection fraction (HFpEF) in women. The key objectives are to: 1) measure the relationship between post-partum subclinical left ventricular diastolic dysfunction and...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $742,984 Cooperative Agreement (CFDA 93.837 Cardiovascular Diseases Research) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct a 3-center, blinded, placebo-controlled, randomized Phase II clinical trial. The trial, titled "EMPAGLIFLOZIN TO IMPROVE RIGHT VENTRICULAR FUNCTION IN PULMONARY ARTERIAL HYPERTENSION (EMPAH)," aims to evaluate whether the drug empagliflozin can...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,545,248 to support a 5-year observational study investigating the longitudinal association between post-infarct lipomatous metaplasia (LM) and malignant arrhythmia in patients with prior myocardial infarction (MI). The study aims to define the relationship between reperfusion injury, LM incidence and progression, and the...

This Project Grant award, totaling $1,862,169.00 and funded by the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 Cardiovascular Diseases Research, supports a comprehensive research initiative to investigate the mechanism of myocardial fibrosis induced by mitral valve prolapse (MVP). The research project, led by The General Hospital Corporation (doing business as Massachusetts General Hospital), aims to elucidate the link between altered mechanical forces caused by MVP and...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,518,070 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Methodist Hospital Research Institute (HMRI) to conduct research on sudden cardiac death risk assessment and mechanistic insights in arrhythmic mitral valve prolapse (MVP). The 5-year project, starting September 2024, aims to: 1) perform deep phenotyping of MVP patients to understand characteristics and mechanisms associated with ventricular...

The federal Project Grant award of $100,050.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to investigate the potential role of cardiometabolic drugs, such as glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2I), as well as the repurposing of metformin and bariatric surgery, in reducing the burden of atrial fibrillation (AF). The research...

This $374,592.00 Project Grant awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program will support Dr. Lachant's research on an electronically-delivered home rehabilitation program for patients recovering from acute pulmonary embolism. The goal is to evaluate whether a prescriptive, gradually intensifying 8-week exercise program delivered remotely is more effective than regular electronic contact in reducing "post-PE...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $601,075 to The Trustees of the University of Pennsylvania to evaluate factors contributing to delayed diagnosis of peripartum cardiomyopathy (PPCM), particularly among Black women. The key objectives are to: 1) determine patient-reported factors that lead to delayed PPCM diagnosis and compare differences between Black and white...

This Project Grant award of $2,340,483.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research to enhance the clinical identification of individuals at risk of moderate to severe mitral valve prolapse (MVP) and associated adverse health outcomes. The key objectives are to: 1) describe the history of MVP and related cardiac morbidities using a large population dataset from Intermountain Healthcare; 2) evaluate heritable risk...

This $604,115 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a longitudinal observational study by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop non-invasive advanced imaging technologies to predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis interstitial lung...